Draft Adhesion Barrier Guidance Overly Burdensome - Industry Task Force
This article was originally published in The Gray Sheet
Executive Summary
FDA's proposal that clinical studies of resorbable adhesion barrier devices have endpoints other than adhesion reduction is overly burdensome to manufacturers, according to an industry task force.